Pieris Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 20.09 million compared to USD 3.47 million a year ago. Revenue was USD 20.06 million compared to USD 3.7 million a year ago. Net income was USD 3.98 million compared to net loss of USD 10.34 million a year ago. Basic earnings per share from continuing operations was USD 4 compared to basic loss per share from continuing operations of USD 11.2 a year ago. Diluted earnings per share from continuing operations was USD 4 compared to diluted loss per share from continuing operations of USD 11.2 a year ago.
For the six months, sales was USD 22.1 million compared to USD 14.65 million a year ago. Revenue was USD 21.99 million compared to USD 14.69 million a year ago. Net loss was USD 9.21 million compared to USD 15.44 million a year ago. Basic loss per share from continuing operations was USD 8.8 compared to USD 16.8 a year ago. Diluted loss per share from continuing operations was USD 8.8 compared to USD 16.8 a year ago.